(Q36364980)

13 August 2017

1 reference

title

Emerging treatments for bipolar disorder: safety and adverse effect profiles (English)

1 reference

13 August 2017

1 reference

Patricia A Marken

1

1 reference

13 August 2017

Ronald W Pies

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

10 January 2006

1 reference

Annals of Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

40

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

276-285

1 reference

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs

13 August 2017

cites work

1 reference

Obesity as a correlate of outcome in patients with bipolar I disorder

21 January 2018

1 reference

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania

21 January 2018

1 reference

Antipsychotic drugs in bipolar disorder

21 January 2018

1 reference

Efficacy and safety of novel antipsychotics: a critical review

21 January 2018

1 reference

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

21 January 2018

1 reference

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

The role of atypical antipsychotics in bipolar depression and anxiety disorders

21 January 2018

1 reference

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

21 January 2018

1 reference

Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses

21 January 2018

1 reference

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database

21 January 2018

1 reference

Fatal olanzapine-induced ketoacidosis

21 January 2018

1 reference

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine

21 January 2018

1 reference

Risperidone-associated diabetes mellitus: a pharmacovigilance study

21 January 2018

1 reference

Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study

21 January 2018

1 reference

Combination of mood stabilizers with quetiapine for treatment of acute bipolar disorder: an open label study

21 January 2018

1 reference

Use of quetiapine in bipolar disorder: a case series with prospective evaluation

21 January 2018

1 reference

Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study

21 January 2018

1 reference

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

21 January 2018

1 reference

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

Ziprasidone: a new atypical antipsychotic

21 January 2018

1 reference

Ziprasidone, a new atypical antipsychotic drug

21 January 2018

1 reference

Ziprasidone: profile on safety

21 January 2018

1 reference

Aripiprazole: profile on efficacy and safety

21 January 2018

1 reference

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

21 January 2018

1 reference

21 January 2018

1 reference

Management of the adverse effects of clozapine

21 January 2018

1 reference

Atypical antipsychotics and hyperglycaemia

21 January 2018

1 reference

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

21 January 2018

1 reference

Safety and tolerability of lamotrigine for bipolar disorder

21 January 2018

1 reference

Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment

21 January 2018

1 reference

New anticonvulsant medication uses in bipolar disorder

21 January 2018

1 reference

Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability

21 January 2018

1 reference

Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design

21 January 2018

1 reference

Use of topiramate in treatment-resistant bipolar spectrum disorders.

21 January 2018

1 reference

Adjunctive topiramate in bipolar II disorder

21 January 2018

1 reference

Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study

21 January 2018

1 reference

The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder

21 January 2018

1 reference

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

21 January 2018

1 reference

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

An open label study of gabapentin in the treatment of acute mania.

21 January 2018

1 reference

Changes in body weight with chronic, high-dose gabapentin therapy

21 January 2018

1 reference

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

21 January 2018

1 reference

Efficacy and safety of zonisamide: results of a multicenter study.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G112

1 reference

13 August 2017

1 reference